Interaksi Dosetaksel

The alcohol content in a dose of Docetaxel Injection may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. (label Dosetaksel, Peringatan kotak hitam)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (label Dosetaksel, Interaksi obat)

In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (label Trastuzumab, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

In the adjuvant breast cancer trial (TAX316) AML occurred in 3 of 744 patients who received docetaxel, doxorubicin, and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin, and cyclophosphamide [ see Clinical Studies (14.2) ]. (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

In the 251 patients with metastatic breast cancer who received XELODA with docetaxel, 68% had grade 3 or 4 neutropenia, 2.8% had grade 3 or 4 thrombocytopenia, and 10% had grade 3 or 4 anemia. (label Kapesitabin, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Treatment-related AML or MDS has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. (label Dosetaksel, Peringatan dan perhatian)

In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (label Dosetaksel, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)